Leadartis receives an Investment Award from BIOSPAIN 2012 Investment Forum

28-09-2012

This past 19-21 September, the Bilbao Exhibition Center hosted the BIOSPAIN 2012 Investment Forum. The Investment Forum offers a unique setting with pan-European networking for top entrepreneurs, R&D leaders, investors and experts from the Biotech sector. Companies seeking international financing or partners have the opportunity to present their business projects to a panel of interested investors and corporate partners.

LeadArtis collaborate on next-generation Trimerbody® products

22-03-2012

LeadArtis S.L. announced that published proof-of-concept data with a new Trimerbody® molecule. Trimerbody® molecules based in human collagen XV exhibited excellent antigen binding capacity, and demonstrated greater thermal and serum stability and resistance to protease digestion than conventional type XVIII Trimerbody® molecules.

LeadArtis is an Associated Company to the Immunotherapy Network

21-11-2011

The Immunotherapy Network IMMUNONET is a project approved under the Programme of Territorial Cooperation of the European Southwest Area (SUDOE-Interreg IV B). Bringing together leading international scientists, a stable team of cutting-edge research in Immunotherapy has been established in the southwestern Europe.

Leadartis present at the 5th edition of the Healthcare Investment, Forum Conference on November 3, 2011

04-11-2011

This past 3 November, the Medical Association of Barcelona (COMB) hosted the fifth edition of the Healthcare Investment Forum, a conference which aims to make private funding more accessible to companies in the healthcare sector that are in the growth phase and require an injection of up to 3 million euros of capital. Leadartis was one of the 11 companies selected, from more than 30 candidates, to present the project to more than 100 venture investors.

The CDTI has awarded Leadartis with a NEOTEC loan

01-09-2010

The Center for Industrial Technological Development (www.cdti.es), a Spanish governmental body dependent on the Ministry of Science and Innovation has granted a NEOTEC loan to Leadartis for the development of diagnostic and therapeutic candidates.

Leadartis is part of the Genoma España´s Technology Portfolio

01-02-2008

In 2008 LeadArtis signed an agreement with Genoma España, and it has been incorporated to its Technology Portfolio (www.gen-es.com.es). The agreement supported the creation of the company and represented an infusion of resources to finance LeadArtis´start-up activities.

Syndicate content

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
Read more
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Read more
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...

Read more

Syndicate content